Filing Details
- Accession Number:
- 0001140361-18-023310
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-05-14 16:01:23
- Reporting Period:
- 2018-05-11
- Accepted Time:
- 2018-05-14 16:01:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1636282 | Aeglea Biotherapeutics Inc. | AGLE | Pharmaceutical Preparations (2834) | V8 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1114448 | Ag Novartis | C/O Novartis International Ag Lichtstrasse 35 Basel V8 CH 4056 | No | No | No | No | |
| 1297709 | Ltd Bioventures Novartis | C/O Novartis International Ag Lichtstrasse 35 Basel V8 CH-4056 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-05-11 | 19,550 | $10.06 | 2,175,314 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.25. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
Billionaire Hedge Funds
